Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3001–3024 of 10,825 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Developmental Defect Clear all

Conditions: Duchenne Muscular Dystrophy
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 7 Years to 22 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: DHDDS-Congenital Disorder of Glycosylation, DHDDS-CDG, Congenital Disorder of Glycosylation
Interventions: Nicotinamide Mononucleotide (NMN) Nucleosidase; Drug
Lead sponsor: Eva Morava-Kozicz; Other
Eligibility: 4 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Charcot Marie Tooth Disease
Interventions: Coenzyme Q10, Coenzyme Q10; Drug · Dietary Supplement
Lead sponsor: Memorial Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Johnstown, Pennsylvania

Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 110 Years
Enrollment: 999,999 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2099
U.S. locations: 42
States / cities: Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more

Conditions: Atopic Dermatitis
Interventions: Actigraphy Device; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Maplewood, Missouri

Conditions: Plantar Fasciitis, Equinus Deformity
Interventions: Instep without gastrocnemius recession, Instep with gastrocnemius recession; Procedure
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Dublin, Ohio • Gahanna, Ohio • Grove City, Ohio + 1 more

Conditions: Meditation, Brain; Agenesis
Interventions: Shambhavi Madamudra Kriya; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 20 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Familial Hypercholesterolemia
Interventions: atorvastatin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 6 Years to 15 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 3 more

Conditions: Opioid-use Disorder, Neonatal Abstinence Syndrome, Pregnancy, High Risk, Alcohol Use Disorder
Interventions: Pharmacokinetic analysis, Safety and Efficacy, Genetic and epigenetic analysis, Breast milk analysis; Other · Genetic
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts • Carrboro, North Carolina

Conditions: Cystic Fibrosis
Interventions: Colistin, Tobramycin; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Homocystinuria
Interventions: SYNB1353; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Tuberous Sclerosis Complex, Seizures
Interventions: GWP42003-P, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Year to 65 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 23
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Duchenne Muscular Dystrophy
Interventions: delandistrogene moxeparvovec, placebo; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 7 Years · Male only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 23
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 20 more

Conditions: Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 72
States / cities: Scottsdale, Arizona • Tempe, Arizona • Little Rock, Arkansas + 61 more

Conditions: Upper Limb Deformities, Congenital
Interventions: 3D Printed Myoelectric Prosthetic Device; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 6 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Orlando, Florida • Portland, Oregon

Conditions: Retinitis Pigmentosa
Interventions: Low Dose NT-501, High Dose NT-501; Combination Product
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 18 Years to 68 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 11
States / cities: Beverly Hills, California • Sacramento, California • San Francisco, California + 8 more

Conditions: Lysosomal Storage Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 2
States / cities: San Francisco, California • Washington D.C., District of Columbia

Conditions: Degenerative Disc Disease, Craniocervical Injuries, Cervical Radiculopathy, Cervical Disc Disease, Cervical Fusion, Cervical Spine Disease, Cervical Myelopathy, Cervical Instabilities Spine, Thoracic Injury
Interventions: observational study; Device
Lead sponsor: NuVasive; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 7
States / cities: Orange, California • Hartford, Connecticut • Hyattsville, Maryland + 4 more

Conditions: Skin Diseases
Interventions: Dupilumab; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 6 Months and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cystic Fibrosis
Interventions: sodium nitrite; Drug
Lead sponsor: Schmidhofer, Mark, MD; Individual
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Univentricular Heart
Interventions: LUX-Dx™; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 30 Days
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Immunodeficiency, Agammaglobulinemia, Hypogammaglobulinemia, Antibody Deficiency
Interventions: Kedrion IVIG 10%; Biological
Lead sponsor: Kedrion S.p.A.; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 12
States / cities: Little Rock, Arkansas • North Palm Beach, Florida • Atlanta, Georgia + 8 more

Conditions: Hereditary Breast and Ovarian Cancer
Interventions: Culturally Targeted Narrative Video: "Is My Cancer Hereditary? Rosa Visits a Genetic Counselor.", FORCE Fact Sheet; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 289 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Richmond, Virginia

Conditions: Duchenne Muscular Dystrophy
Interventions: scAAV9.U7.ACCA; Biological
Lead sponsor: Megan Waldrop; Other
Eligibility: 6 Months to 13 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

This is a Study to Get More Information About Non Ambulatory Boys & Men With Duchenne Muscular Dystrophy

Assessing the Safety and Tolerability of NMN in DHDDS-CDG

Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease

Integrated Cancer Repository for Cancer Research

Scratching Validation Study

Instep Plantar Fasciotomy With and Without Gastrocnemius Recession

Brain Health With Inner Engineering Meditation

Atorvastatin Three Year Pediatric Study

MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study

IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy

Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

Prosthetic Device in Children With Upper Congenital Limb Deficiency

A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa

The Classification and Cause of Leukodystrophies of Unknown Cause

Posterior Cervical Fixation Study

Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders

Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis

Interstage Monitoring Using an Implantable Loop Recorder: A Pilot Study

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing

AAV9 U7snRNA Gene Therapy to Treat Boys With DMD Exon 2 Duplications.